Does HPV Vaccine Prevent Cancer—and By How Much?

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. Certain “high-risk” HPV types can lead to cancers of the cervix, anus, penis, vulva, vagina and oropharynx. Vaccination against HPV offers a powerful way to cut your risk of these cancers.

Below, we’ll explain:

• How HPV causes cancer
• How the HPV vaccine works
• The real-world reduction in cancer risk
• Safety considerations
• Who should get vaccinated
• Next steps, including a free symptom check

Throughout, we rely on data from the World Health Organization (WHO), U.S. Centers for Disease Control and Prevention (CDC), major peer-reviewed studies and cancer registries.

---

How HPV Causes Cancer

1. Virus infection
   • More than 200 HPV types exist.
   • “High-risk” types 16 and 18 cause about 70% of cervical cancers worldwide.
   • Types 31, 33, 45, 52 and 58 add roughly another 20%.
2. Cell changes
   • Persistent infection can introduce viral genes into cervix or other tissues.
   • This disrupts normal cell growth and allows early cancerous changes.
3. Progression to cancer
   • It typically takes 10–15 years from initial infection to invasive cancer.
   • Routine screening (Pap and HPV tests) can catch pre-cancerous lesions early.

---

How the HPV Vaccine Works

• Targets high-risk HPV types
  • Bivalent vaccines cover types 16/18.
  • Quadrivalent adds types 6/11 (cause genital warts).
  • 9-valent covers 6/11/16/18 plus five additional high-risk types.
• Stimulates immunity
  • A harmless shell of HPV proteins triggers antibodies.
  • If you’re exposed later, your immune system neutralizes the virus.
• Dosing
  • Two doses for ages 9–14 (six months apart).
  • Three doses for ages 15+ (0, 1–2, and 6 months).

---

Effectiveness: By How Much?

Cervical Cancer and Precancerous Lesions

• CIN2+ (moderate to severe pre-cancer)
  • Meta-analysis shows up to 90% reduction in CIN2+ for HPV-naïve women vaccinated before exposure.
  • Real-world data (Australia, Sweden): 50–70% reduction in CIN2+ even with mixed prior HPV exposure.
• Invasive cervical cancer
  • Sweden study: when vaccinated before age 17, up to 88% lower risk of cervical cancer over 10+ years.
  • Population data: countries with ≥50% coverage see cervical cancer rates drop by 40–50% in vaccinated cohorts.

Other HPV-Related Cancers

• Anal cancer
  • Among men who have sex with men, vaccine reduced high-grade anal lesions by ~75%.
• Oropharyngeal cancer
  • Early evidence suggests vaccine cuts oral HPV infection by ~88%, likely reducing future throat cancers.
• Genital warts
  • Quadrivalent/9-valent vaccines drop wart diagnoses by 80–90% in young people.

Overall Cancer Prevention

• By preventing infection with the most aggressive HPV types, the vaccine is projected to avert:
  • 70% of cervical cancers (bivalent/quadrivalent).
  • Up to 90% of cervical cancers (9-valent).
  • Roughly 90% of genital warts.
  • Significant portions of anal, penile, vulvar and oropharyngeal cancers.

---

Long-Term Impact

• Herd immunity
  • High vaccination rates protect unvaccinated individuals by reducing overall HPV circulation.
• Global goal
  • WHO aims to eliminate cervical cancer as a public health problem by achieving 90% coverage of girls by age 15.
• Screening still vital
  • Vaccinated women should continue Pap/HPV testing as recommended—vaccines don’t cover every cancer-causing HPV type.

---

Safety and Side Effects

• Safety record
  • Over 270 million doses distributed in the U.S. alone.
  • WHO and CDC confirm no serious safety concerns.
• Common mild side effects
  • Injection-site pain, redness or swelling
  • Low-grade fever, headache or dizziness
  • Fainting (rare; observed with many adolescent vaccines; monitored by 15-minute post-vaccination wait)

---

Who Should Get Vaccinated?

• Routine recommendation
  • Girls and boys at age 11–12 (can start as early as 9).
• Catch-up vaccination
  • All individuals up to age 26 who weren’t vaccinated earlier.
• Shared clinical decision
  • Vaccination may be offered to people aged 27–45 after discussing risks and benefits with a doctor.

---

Access and Next Steps

1. Talk to your healthcare provider
   • Confirm your vaccination history.
   • Plan the dosing schedule.
2. Check insurance or public programs
   • In many countries, HPV vaccination is free or low-cost.
3. Stay on schedule
   • Completing all recommended doses maximizes protection.
4. Keep up screening
   • Follow guidelines for Pap and HPV tests as you age.

---

Check Your Symptoms

If you ever notice unusual symptoms such as abnormal bleeding, persistent throat soreness or lumps, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.

---

Speak to a Doctor

Vaccination offers the best defense against multiple HPV-related cancers, preventing up to 90% of cases caused by covered strains. If you have questions about HPV, vaccine timing, or any concerning symptoms, always speak to a doctor, nurse or other qualified healthcare professional—especially if something feels life-threatening or serious.